News
INDP
2.025
-3.57%
-0.075
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
Graham, Appian And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga · 2d ago
Weekly Report: what happened at INDP last week (0601-0605)?
Weekly Report · 2d ago
Why Marvell Technology Shares Are Trading Higher By 7%; Here Are 20 Stocks Moving Premarket
Benzinga · 2d ago
Indaptus Therapeutics Announces Recent Board and Leadership Changes
TipRanks · 4d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 4d ago
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 4d ago
Pre-Market Movers: BGMS, CMND, INDP Chart The Course
NASDAQ · 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 5d ago
Why Solidion Technology Shares Are Rallying Over 50%; Here Are 20 Stocks Moving Premarket
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 5d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 5d ago
Thursday Sector Leaders: Advertising, Biotechnology Stocks
NASDAQ · 5d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 06/02 21:09
Weekly Report: what happened at INDP last week (0525-0529)?
Weekly Report · 06/01 10:13
Top Biotech Gainers: AKTX Rallies; GOVX Up On Ebola Concerns; SLGL Awaits Catalysts; CMMB On Watch
NASDAQ · 05/26 07:50
Weekly Report: what happened at INDP last week (0518-0522)?
Weekly Report · 05/25 10:16
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 05/21 17:05
Weekly Report: what happened at INDP last week (0511-0515)?
Weekly Report · 05/18 10:16
Indaptus Therapeutics GAAP EPS of -$0.23
Seeking Alpha · 05/15 13:11
More
Webull provides a variety of real-time INDP stock news. You can receive the latest news about Indaptus Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About INDP
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.